Is The Market Rewarding Shinva Medical Instrument Co.,Ltd. (SHSE:600587) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Is The Market Rewarding Shinva Medical Instrument Co.,Ltd. (SHSE:600587) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Shinva Medical InstrumentLtd (SHSE:600587) has had a rough three months with its share price down 14%. It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Fundamentals usually dictate market outcomes so it makes sense to study the company's financials. Particularly, we will be paying attention to Shinva Medical InstrumentLtd's ROE today.
Shinva Medical Instrument Ltd(SHSE:600587)在過去三個月中股價下跌了14%。可能是因爲市場忽略了該公司不同的財務狀況並決定傾向於負面情緒。基本面通常決定市場結果,因此研究公司的財務狀況是有道理的。今天我們將特別關注 Shinva Medical Instrument Ltd 的ROE。
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.
股東要考慮的關鍵因素之一是淨資產收益率或roe,因爲它告訴他們公司如何有效地重新投資他們的資本。簡單點說,它衡量了公司與股東權益相關的盈利能力。
How Is ROE Calculated?
淨資產收益率怎麼計算?
ROE can be calculated by using the formula:
淨資產收益率可以使用以下公式進行計算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益
So, based on the above formula, the ROE for Shinva Medical InstrumentLtd is:
所以,基於以上公式,Shinva Medical Instrument Ltd 的 ROE 爲:
8.8% = CN¥689m ÷ CN¥7.9b (Based on the trailing twelve months to March 2024).
8.8%= CN¥68900萬 ÷ CN¥79億(基於最近 12 個月到 2024 年 3 月)。
The 'return' is the yearly profit. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.09 in profit.
‘回報’是每年的利潤,這意味着公司每CN¥1的股東權益產生CN¥0.09的利潤。
What Has ROE Got To Do With Earnings Growth?
ROE與盈利增長有什麼關係?
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
到目前爲止,我們了解到ROE是衡量一家公司如何高效地產生利潤的指標。 根據公司選擇重新投資或“保留”的利潤的比例,我們能夠評估公司未來產生利潤的能力。 假設其他所有內容保持不變,則ROE和盈利保留比越高,公司的增長速度就越高,這與那些不一定具備這些特徵的公司相比。
A Side By Side comparison of Shinva Medical InstrumentLtd's Earnings Growth And 8.8% ROE
Shinva Medical Instrument Ltd 收益增長和8.8% ROE 的並列比較
When you first look at it, Shinva Medical InstrumentLtd's ROE doesn't look that attractive. Yet, a closer study shows that the company's ROE is similar to the industry average of 7.4%. We can see that Shinva Medical InstrumentLtd has grown at a five year net income growth average rate of 4.3%, which is a bit on the lower side. Remember, the company's ROE is not particularly great to begin with. So this could also be one of the reasons behind the company's low growth in earnings.
當你首次看到它時,Shinva Medical Instrument Ltd 的 ROE 看起來並不那麼有吸引力。然而,更近距離的研究表明,該公司的 ROE 與行業平均水平相似,爲7.4%。我們看到 Shinva Medical Instrument Ltd 的五年淨利潤增長平均速率爲4.3%,有點偏低。請記住,公司的 ROE 起點並不是特別高。因此,這可能也是公司盈利增長緩慢的原因之一。
As a next step, we compared Shinva Medical InstrumentLtd's net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 6.5% in the same period.
作爲下一步,我們將 Shinva Medical Instrument Ltd 的淨利潤增長與行業進行了比較,很失望地發現公司的增長低於同期行業平均增長率6.5%。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240620/0-205d86ee4d0b31889169d76971fae8b1-0-0c6dd6baa3d84a00e67e54a7faac4f08.png/big)
Earnings growth is an important metric to consider when valuing a stock. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Shinva Medical InstrumentLtd fairly valued compared to other companies? These 3 valuation measures might help you decide.
收益增長是估值股票時必須考慮的重要指標。投資者應該努力確立股票的預期增長或下降是否已被定價。通過這樣做,他們將了解股票是否進入了清澈的藍色水域,或者沼澤水域正在等待着。與其他公司相比,Shinva Medical Instrument Ltd 是否被公平估值?這 3 個估值措施可能會幫助您決定。
Is Shinva Medical InstrumentLtd Efficiently Re-investing Its Profits?
Shinva Medical Instrument Ltd 是否有效地再投資利潤?
Shinva Medical InstrumentLtd's low three-year median payout ratio of 11% (or a retention ratio of 89%) should mean that the company is retaining most of its earnings to fuel its growth. This should be reflected in its earnings growth number, but that's not the case. Therefore, there might be some other reasons to explain the lack in that respect. For example, the business could be in decline.
Shinva Medical Instrument Ltd 三年低中位支付比率僅爲11%(或保留比率爲89%),這應表明公司將大部分利潤留作增長資本。這應在其盈利增長數字中反映出來,但事實並非如此。因此,可能還有其他原因來解釋其中的缺陷。例如,業務可能處於下降趨勢。
Moreover, Shinva Medical InstrumentLtd has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth.
此外,Shinva Medical Instrument Ltd 已連續十年或更長時間支付股息,這表明管理層認爲股東更喜歡股息而不是盈利增長。
Summary
總的來說,我們對偉明環保的表現非常滿意。具體而言,我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然,這導致公司的收益大幅增長。但是,最新的行業分析師預測表明,該公司的收益預計將加速增長。
Overall, we have mixed feelings about Shinva Medical InstrumentLtd. While the company does have a high rate of reinvestment, the low ROE means that all that reinvestment is not reaping any benefit to its investors, and moreover, its having a negative impact on the earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總的來說,我們對Shinva Medical Instrument Ltd 的感覺是複雜的。雖然公司的再投資率很高,但ROE很低,這意味着所有的再投資並沒有爲其投資者帶來任何好處,並且對盈利增長產生了負面影響。儘管如此,從目前的分析師預測來看,我們發現公司的收益預計會加速增長。要了解有關公司未來盈利增長預測的更多信息,請查看分析師預測公司的免費報告以了解更多。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com